Keith Katkin
Chairman at ELEDON PHARMACEUTICALS, INC.
Net worth: 1 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dennis Podlesak | M | 66 |
Peninsula Pharmaceuticals, Inc.
 Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA.
Transposon Therapeutics, Inc.
 Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | 20 years |
| Christine Ocampo | F | 51 |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 16 years |
| Bryan Smith | M | 45 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| James Robinson | M | 54 | 5 years | |
| Pierre Legault | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 7 years |
| Michael Metzger | M | 53 | 9 years | |
| Sef P. Kurstjens | M | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Keith Goldan | M | 52 | 2 years | |
| Shigeyuki Nishinaka | M | 59 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 years |
| Steven Perrin | M | 59 | 4 years | |
| Myrtle Potter | F | 65 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Eckard Weber | M | 73 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA.
Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | - |
| Marvin White | M | 61 |
Indiana University
| 7 years |
| Gregg Lapointe | M | 65 | 7 years | |
| Zsolt Pál Harsányi | M | 80 | 20 years | |
| David-Alexandre Gros | M | 51 | 4 years | |
| Donald DeGolyer | M | 63 | 1 years | |
| Jennifer Fox | F | 51 | 6 years | |
| Kelly Parker | M | - | 9 years | |
| Richard Lindahl | M | 70 | 6 years | |
| Alison Hannah | M | 63 | 3 years | |
| Jennifer Jarrett | F | 53 | 6 years | |
| Kathryn Zoon | M | 75 | 8 years | |
| Brian Kotzin | M | 74 | 7 years | |
| Jan Hillson | M | 71 | 3 years | |
| Nori Ebersole | F | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 7 years |
| Catherine Madigan | M | 52 | - | |
| Paul Little | M | 60 | 3 years | |
| June Lee | M | 58 | 4 years | |
| Martin Huber | M | 64 | 3 years | |
| David Hovland | M | - | 6 years | |
| William Meury | M | 56 | 6 years | |
| Louis Sullivan | M | 90 | 19 years | |
| Walter Ogier | M | 67 | 4 years | |
| Ronald Richard | M | 68 | 19 years | |
| Joseph Papa | M | 68 | - | |
| Allan Kirk | M | - | 1 years | |
| Luke Albrecht | M | 45 | 8 years | |
| Jane Wasman | F | 67 | 5 years | |
| Sharon P. Klahre | F | - | 2 years | |
| Neal Fowler | M | 62 | 1 years | |
| John McBride | M | 72 | 7 years | |
| Peter Ordentlich | M | 55 | 19 years | |
| Kamil Ali-Jackson | F | 65 | 3 years | |
| Sujata Dayal | F | 61 | 2 years | |
| Neil Gallagher | M | 60 | 1 years | |
| John Herberger | M | - | 2 years | |
| BT Slingsby | M | - |
Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | - |
| Coleen Glessner | F | 53 | 4 years | |
| Aubrey Watkins | M | - | - | |
| Aneta Ferguson | F | - | 9 years | |
| Stephanie Duatschek | F | - | - | |
| Jack A. Bowling | M | - |
Brain Injury Association of America, Inc.
| - |
| Julie Patel | F | - | 2 years | |
| Kevin McManus | M | - | 1 years | |
| Cornelia Haag-Molkenteller | M | 66 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Christopher W. Frech | M | - | 15 years | |
| Laura Kennedy | F | - | 8 years | |
| Sharon Solomon | F | - | 7 years | |
| Heather N. Vinas | F | 44 |
Brain Injury Association of America, Inc.
| - |
| Dean Schorno | M | 61 | 6 years | |
| Bill Harrington | M | - |
Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | - |
| John Pacifico | M | - |
Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | - |
| Brent Ahrens | M | 61 |
Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | - |
| Eliezer Katz | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Kramer | M | 66 | 24 years | |
| Jon S. Kuwahara | M | 59 | 7 years | |
| Richard Shea | M | 72 | 6 years | |
| Fuad El Hibri | M | 66 | 24 years | |
| Rohan Palekar | M | 58 | 5 years | |
| Michael McFadden | M | 57 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 9 years |
| Erez Chimovits | M | 60 |
Otic Pharma Ltd.
 Otic Pharma Ltd. Pharmaceuticals: MajorHealth Technology Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA. | 3 years |
| Jodie Morrison | F | 48 | 5 years | |
| Gregory P. Hanson | M | 77 | 8 years | |
| Gregory Flesher | M | 54 | 13 years | |
| Briggs Morrison | M | 65 | 9 years | |
| Catherine Turkel | M | 63 |
Otic Pharma Ltd.
Otic Pharma Ltd. Pharmaceuticals: MajorHealth Technology Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA. | 5 years |
| Michael Cruse | M | 52 | 14 years | |
| Atul Saran | M | 50 | 6 years | |
| Alexander Nolte | M | 52 | 6 years | |
| Donald G. Payan | M | 75 | 20 years | |
| Eric Brandt | M | 62 | 2 years | |
| Kim Kamdar | M | 56 | 11 years | |
| Bong-Joo Lee | M | 64 |
Indiana University
| 6 years |
| Terry Stapp | M | - |
Indiana University
| 8 years |
| Keith M. McGahan | M | - | 1 years | |
| Stephen Sherwin | M | 75 | 17 years | |
| Luke Evnin | M | 60 | 6 years | |
| Stephen G. Austin | M | 71 | 9 years | |
| Henry Chen | M | 53 | 3 years | |
| Cheryl L. Cohen | F | 58 | 5 years | |
| Joanna L. Moore | F | - | - | |
| Michael Curless | M | 60 |
Indiana University
| 7 years |
| Peter S. Ringrose | M | 78 | 14 years | |
| Steven Basta | M | 59 |
Carbylan Therapeutics, Inc.
 Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA. | 7 years |
| Bob Miller | M | - |
Indiana University
| 8 years |
| Bruce E. Beerbower | M | - |
Indiana University
| 5 years |
| Anand Deshpande | M | 62 |
Indiana University
| 4 years |
| John T. Hackett | M | 89 |
Indiana University
| 3 years |
| David Saul | M | - |
Carbylan Therapeutics, Inc.
Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
| United Kingdom | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Keith Katkin
- Personal Network
